Bausch Health Cos Inc. (NYSE:BHC) Receives Consensus Rating of "Reduce" from Analysts

Shares of Bausch Health Cos Inc. (NYSE:BHC - Get Free Report) have received a consensus rating of "Reduce" from the six analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and five have issued a hold recommendation on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $7.30.

BHC has been the topic of a number of recent analyst reports. Royal Bank Of Canada increased their price target on shares of Bausch Health Cos from $8.50 to $10.00 and gave the stock a "sector perform" rating in a research note on Friday, May 2nd. Wall Street Zen downgraded Bausch Health Cos from a "buy" rating to a "hold" rating in a report on Saturday, May 10th.

Insider Activity

In other Bausch Health Cos news, Director John Paulson bought 3,564,059 shares of Bausch Health Cos stock in a transaction that occurred on Friday, June 13th. The shares were acquired at an average price of $5.94 per share, for a total transaction of $21,170,510.46. Following the acquisition, the director owned 32,791,702 shares of the company's stock, valued at $194,782,709.88. The trade was a 12.19% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have acquired a total of 6,352,667 shares of company stock valued at $35,870,767 over the last ninety days. 8.05% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in BHC. SBI Securities Co. Ltd. boosted its position in shares of Bausch Health Cos by 244.2% in the first quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company's stock worth $27,000 after buying an additional 3,001 shares during the period. Cary Street Partners Financial LLC acquired a new position in Bausch Health Cos during the 1st quarter worth approximately $27,000. Caitong International Asset Management Co. Ltd purchased a new position in Bausch Health Cos in the 1st quarter worth approximately $27,000. Mountain Hill Investment Partners Corp. purchased a new position in Bausch Health Cos in the 4th quarter worth approximately $56,000. Finally, Wealthquest Corp acquired a new stake in Bausch Health Cos in the first quarter valued at approximately $58,000. 78.65% of the stock is owned by hedge funds and other institutional investors.

Bausch Health Cos Trading Up 0.8%

Shares of NYSE BHC traded up $0.06 on Thursday, reaching $6.65. 2,265,284 shares of the company traded hands, compared to its average volume of 2,605,965. The stock has a market capitalization of $2.46 billion, a PE ratio of -60.41 and a beta of 0.41. Bausch Health Cos has a fifty-two week low of $3.96 and a fifty-two week high of $9.85. The company has a 50 day moving average of $5.39 and a 200 day moving average of $6.25.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.